Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging

Sara Sheikhbahaei, Ali Afshar-Oromieh, Matthias Eiber, Lilja Solnes, Mehrbod Som Som Javadi, Ashley E. Ross, Kenneth Pienta, Mohamad E Allaf, Uwe Haberkorn, Martin Gilbert Pomper, Michael Gorin, Steven Rowe

Research output: Contribution to journalArticle

Abstract

Background: The rapidly expanding clinical adaptation of prostate-specific membrane antigen (PSMA)-targeted PET imaging in the evaluation of patients with prostate cancer has placed an increasing onus on understanding both the potential pearls of interpretation as well as limitations of this new technique. As with any new molecular imaging modality, accurate characterization of abnormalities on PSMA-targeted PET imaging can be accomplished only if one is aware of the normal distribution pattern, physiological variants of radiotracer uptake, and potential sources of false-positive and false-negative imaging findings. In recent years, a growing number of reports have come to light describing incidental non-prostatic benign or malignant pathologies with high uptake on PSMA-targeted PET imaging. In this review, we have summarized the published literature regarding the potential pearls and technical and interpretive pitfalls of this imaging modality. Knowledge of these limitations can increase the confidence of interpreting physicians and thus improve patient care. Conclusions: As PSMA-targeted PET is expected to be evaluated in larger prospective trials, the dissemination of potential diagnostic pitfalls and the biologic underpinning of those findings will be of increased importance.

Original languageEnglish (US)
Pages (from-to)1-20
Number of pages20
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
DOIs
StateAccepted/In press - Aug 1 2017

Fingerprint

Molecular Imaging
Normal Distribution
Prostatic Neoplasms
Patient Care
Pathology
Physicians
human glutamate carboxypeptidase II

Keywords

  • Pearls and pitfalls
  • PET/CT
  • Prostate cancer
  • Prostate-specific membrane antigen
  • PSMA

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. / Sheikhbahaei, Sara; Afshar-Oromieh, Ali; Eiber, Matthias; Solnes, Lilja; Javadi, Mehrbod Som Som; Ross, Ashley E.; Pienta, Kenneth; Allaf, Mohamad E; Haberkorn, Uwe; Pomper, Martin Gilbert; Gorin, Michael; Rowe, Steven.

In: European Journal of Nuclear Medicine and Molecular Imaging, 01.08.2017, p. 1-20.

Research output: Contribution to journalArticle

@article{5b428e8082754767aebb95916a493aed,
title = "Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging",
abstract = "Background: The rapidly expanding clinical adaptation of prostate-specific membrane antigen (PSMA)-targeted PET imaging in the evaluation of patients with prostate cancer has placed an increasing onus on understanding both the potential pearls of interpretation as well as limitations of this new technique. As with any new molecular imaging modality, accurate characterization of abnormalities on PSMA-targeted PET imaging can be accomplished only if one is aware of the normal distribution pattern, physiological variants of radiotracer uptake, and potential sources of false-positive and false-negative imaging findings. In recent years, a growing number of reports have come to light describing incidental non-prostatic benign or malignant pathologies with high uptake on PSMA-targeted PET imaging. In this review, we have summarized the published literature regarding the potential pearls and technical and interpretive pitfalls of this imaging modality. Knowledge of these limitations can increase the confidence of interpreting physicians and thus improve patient care. Conclusions: As PSMA-targeted PET is expected to be evaluated in larger prospective trials, the dissemination of potential diagnostic pitfalls and the biologic underpinning of those findings will be of increased importance.",
keywords = "Pearls and pitfalls, PET/CT, Prostate cancer, Prostate-specific membrane antigen, PSMA",
author = "Sara Sheikhbahaei and Ali Afshar-Oromieh and Matthias Eiber and Lilja Solnes and Javadi, {Mehrbod Som Som} and Ross, {Ashley E.} and Kenneth Pienta and Allaf, {Mohamad E} and Uwe Haberkorn and Pomper, {Martin Gilbert} and Michael Gorin and Steven Rowe",
year = "2017",
month = "8",
day = "1",
doi = "10.1007/s00259-017-3780-7",
language = "English (US)",
pages = "1--20",
journal = "European Journal of Nuclear Medicine and Molecular Imaging",
issn = "1619-7070",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging

AU - Sheikhbahaei, Sara

AU - Afshar-Oromieh, Ali

AU - Eiber, Matthias

AU - Solnes, Lilja

AU - Javadi, Mehrbod Som Som

AU - Ross, Ashley E.

AU - Pienta, Kenneth

AU - Allaf, Mohamad E

AU - Haberkorn, Uwe

AU - Pomper, Martin Gilbert

AU - Gorin, Michael

AU - Rowe, Steven

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Background: The rapidly expanding clinical adaptation of prostate-specific membrane antigen (PSMA)-targeted PET imaging in the evaluation of patients with prostate cancer has placed an increasing onus on understanding both the potential pearls of interpretation as well as limitations of this new technique. As with any new molecular imaging modality, accurate characterization of abnormalities on PSMA-targeted PET imaging can be accomplished only if one is aware of the normal distribution pattern, physiological variants of radiotracer uptake, and potential sources of false-positive and false-negative imaging findings. In recent years, a growing number of reports have come to light describing incidental non-prostatic benign or malignant pathologies with high uptake on PSMA-targeted PET imaging. In this review, we have summarized the published literature regarding the potential pearls and technical and interpretive pitfalls of this imaging modality. Knowledge of these limitations can increase the confidence of interpreting physicians and thus improve patient care. Conclusions: As PSMA-targeted PET is expected to be evaluated in larger prospective trials, the dissemination of potential diagnostic pitfalls and the biologic underpinning of those findings will be of increased importance.

AB - Background: The rapidly expanding clinical adaptation of prostate-specific membrane antigen (PSMA)-targeted PET imaging in the evaluation of patients with prostate cancer has placed an increasing onus on understanding both the potential pearls of interpretation as well as limitations of this new technique. As with any new molecular imaging modality, accurate characterization of abnormalities on PSMA-targeted PET imaging can be accomplished only if one is aware of the normal distribution pattern, physiological variants of radiotracer uptake, and potential sources of false-positive and false-negative imaging findings. In recent years, a growing number of reports have come to light describing incidental non-prostatic benign or malignant pathologies with high uptake on PSMA-targeted PET imaging. In this review, we have summarized the published literature regarding the potential pearls and technical and interpretive pitfalls of this imaging modality. Knowledge of these limitations can increase the confidence of interpreting physicians and thus improve patient care. Conclusions: As PSMA-targeted PET is expected to be evaluated in larger prospective trials, the dissemination of potential diagnostic pitfalls and the biologic underpinning of those findings will be of increased importance.

KW - Pearls and pitfalls

KW - PET/CT

KW - Prostate cancer

KW - Prostate-specific membrane antigen

KW - PSMA

UR - http://www.scopus.com/inward/record.url?scp=85026506132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026506132&partnerID=8YFLogxK

U2 - 10.1007/s00259-017-3780-7

DO - 10.1007/s00259-017-3780-7

M3 - Article

SP - 1

EP - 20

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

SN - 1619-7070

ER -